Cambrian Biopharma is a therapeutics company focused on developing transformative medicines by leveraging the power of biotechnology. It operates as a pipeline company, advancing novel treatments through clinical trials. Cambrian Bio's approach involves creating and supporting multiple therapeutic companies, each targeting different areas of high unmet medical need.

Cambrian Bio is a clinical-stage drug development company building the medicines that will modernize healthcare in the 21st century. Our focus lies in creating innovative therapeutics designed to prevent diseases and lengthen healthspan—the period of life spent in good health. 

As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.

To date, we have more than a dozen programs (PipeCos) in our pipeline, including Amplifier Therapeutics (developing a peripherally restricted pan-AMPK activator for the treatment of cardiometabolic diseases), Tornado Therapeutics (developing safer, more effective mTOR inhibitors for extended healthspan), and our latest addition, Telos Biotech (enhancing cell therapies to overcome senescence and exhaustion). We also has programs focused on Women’s Health and Aging (Oviva Therapeutics), Fibrosis (Isterian Biotech), and cellular engineering (Vita Therapeutics).

Sensei Biotherapeutics

Arcellx

Delphi VC

FJ Labs

Mount Nebo Investments LLC

NJF Capital

Infinitas Capital

Korify Capital

Mike Novogratz

Sprint Vc

SALT Fund

Future Ventures

Alumni Ventures

Anthos Capital

Apeiron Investment Group

Kliwla Family Office AG

Moore Capital

Cambrian Bio

Cambrian Biopharma

COM:CAMBRIANBIO

Cambrian Biopharma

Analysis Not Available